FindTrial
Sign In

The efficacy and safety of hysteroscopic endometriectomy for the treatment of torrimifen in the endometrial lesions of postoperative breast cancer patients

The efficacy and safety of hysteroscopic endometriectomy for the treatment of torrimifen in the endometrial lesions of postoperative breast cancer patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-17014136
Enrollment
Unknown
Registered
2017-12-25
Start date
2018-01-17
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

the treatment group and the traditional surgery group:none

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients with breast cancer after surgical inpatient surgery, taking torrimifen daily after surgery, continued to be greater than or equal to December; 2. Irregular vaginal bleeding; 3. Vaginal ultrasonography: the thickness of endometrium is greater than 5mm or abnormal echo of the uterus; 4. Agree to perform hysteroscopy, understand and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with endometrial malignancy, precancerous lesions or cervical lesions; 2. Vaginal bleeding caused by pregnancy related bleeding, infection, blood system disease, liver and kidney diseases, etc

Design outcomes

Primary

MeasureTime frame
endometrial thickness;—

Countries

China

Contacts

Public ContactZhou Yan

Shanghai Sixth People's Hospital

lantu111@126.com+86 15021971677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026